HC Deb 18 July 2003 vol 409 c949W
Mr. Baron

To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the use of(a) clopidogrel and (b) dipyridamole for the prevention of (i) occlusive vascular and (ii) arterosclerotic events. [127032]

Miss Melanie Johnson

The National Institute for Clinical Excellence (NICE) is appraising the clinical and cost effectiveness of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. NICE expects to publish guidance in June 2004. Further details are available on NICE'S website at www.nice.org.uk